BioCentury
ARTICLE | Clinical News

Alagebrium: Phase II delayed

February 28, 2005 8:00 AM UTC

ALT halted enrollment in a open-label Phase II trial due to preclinical toxicity in rats (see BioCentury, Jan. 3). The trial will continue in the patients already enrolled. Additional preclinical data...